Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE

DOI: 10.53555/jptcp.v29i04.4351

ANTIFUNGAL AGENTS: A COMPREHENSIVE REVIEW OF MECHANISMS AND APPLICATIONS

Manju Singh[1], Neha[2], Gurpreet[3], Arvind Rathour[4], Uma Dey[5], Dr. Praveen Kumar Gaur[6], Vijay Kumar[7*]

[1,2,3]Dr. K.N. Modi Institute of Pharmaceutical Education and Research, Modinagar, Uttar Pradesh-201204
[4]School of Pharmacy, Monad University, N.H. 9, Delhi Hapur Road, Dist. Hapur (U.P), Pilkhuwa-245304
[5]H.R. Institute of Pharmacy, Ghaziabad, 7th KM Stone Delhi Meerut Road Morta Ghaziabad, UP- 201003
[6]Metro College of Health Science and Research, Knowledge Park 3, Greater Noida, Uttar Pradesh-201308
[7*]Deparment of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard New Delhi, India- 110062
[1]Dr. A.P.J. Abdul Kalam Technical University,

***Corresponding Author:** Vijay Kumar
*Research Scholar School of Pharmaceutical Education and Research, Jamia Hamdard University, New Delhi, India- 110062vijaypharma1997@gmail.com 8470052097

Abstract:

Introduction: Antifungal resistance poses a significant challenge in the management of fungal infections. Understanding the mechanisms of action of antifungal agents is crucial for developing effective treatment strategies.

Objective: This comprehensive review delves into the intricate world of antifungal agents, offering insights into their diverse mechanisms, current applications, and potential future directions.

Material and Methods: An overview of the existing literature on natural products and semi-synthetic compounds with anti-fungal properties, highlighting their effectiveness against fungal pathogens. It categorizes these compounds based on their structures, sources, anti-fungal effects, and mechanisms of action. Specifically, it delves into various groups of natural compounds and semi-synthetic derivatives, elucidating their impacts on fungal cells by disrupting anabolic processes, signaling pathways, and intracellular substance transport. Moreover, it discusses how the mechanisms and targets of these anti-fungal agents vary across different compounds.

Result: Polyene Antifungals: Disruption of fungal cell membrane integrity through binding to ergosterol. Azoles: Inhibition of ergosterol biosynthesis via binding to lanosterol 14α-demethylase. Echinocandins: Inhibition of β-(1,3)-D-glucan synthesis, leading to cell wall destabilization. Allylamines: Inhibition of squalene epoxidase, a key enzyme in ergosterol biosynthesis. Interference with nucleic acid synthesis by inhibiting dihydrofolate reductase. Efflux pumps: Extrusion of antifungal agents from fungal cells, reducing intracellular drug concentrations. Target alteration:

Mutations in drug targets, such as lanosterol 14α-demethylase or β-(1,3)-D-glucan synthase, impairing drug binding. Ergosterol pathway alterations: Upregulation of alternative pathways bypassing drug targets. Biofilm formation: Enhanced resistance through biofilm-mediated protection. Systemic Treatment of invasive fungal infections, including candidiasis and aspergillosis. Topical Management of superficial fungal infections like dermatophytosis and candidiasis. Prevention of fungal infections in high-risk patients, such as those undergoing chemotherapy or organ transplantation. Control of fungal infections in animals, improving livestock health and production.

Challenges and Future Perspectives: Emergence of multidrug-resistant fungal strains. Development of novel antifungal agents with improved efficacy and safety profiles. Strategies to overcome resistance mechanisms, including combination therapy and drug repurposing. Importance of surveillance programs to monitor antifungal resistance trends globally.

Conclusion: Antifungal agents play a critical role in the management of fungal infections. Continued research efforts are necessary to address challenges associated with antifungal resistance and to develop innovative therapeutic approaches.

Keywords: Antifungal agents, Mechanisms of action, Immunomodulation, Azoles, Antifungal Therapy

1 Introduction:

Fungal infections, once overshadowed by bacterial and viral counterparts, have emerged as a significant global health concern. The increasing incidence of fungal diseases, ranging from superficial infections to life-threatening systemic conditions, necessitates a comprehensive understanding of antifungal agents (Odds et al. 2003; Ryder 1999). This review seeks to unravel the intricate web of mechanisms employed by various antifungal agents and explore their diverse applications in clinical practice. The landscape of antifungal therapy is vast and continuously evolving, driven by the challenges posed by emerging fungal pathogens and the rising threat of drug resistance. As the healthcare community faces the need for effective and adaptable treatment strategies, a detailed examination of the mechanisms of action and applications of existing antifungal agents becomes paramount.

This comprehensive review will delve into the major classes of antifungal agents, providing a nuanced analysis of their mechanisms of action at the cellular and molecular levels. By understanding how these agents interact with fungal pathogens, clinicians and researchers can better appreciate their efficacy, potential limitations, and areas of innovation (Brauer et al. 2019; Mussin and Giusiano 2022). Furthermore, the review aims to bridge the gap between laboratory research and clinical applications by highlighting the practical aspects of antifungal therapy. From common superficial infections to complex systemic diseases, each application presents unique challenges that require a tailored approach. By elucidating these challenges and potential solutions, this review aims to equip healthcare professionals with the knowledge needed to make informed decisions in the management of fungal infections (Mani Chandrika and Sharma 2020). Antifungal medications fall into several categories, each with distinct mechanisms of action (Kumar et al. 2020). Azoles, for example, inhibit the synthesis of ergosterol, a crucial component of fungal cell membranes. Polyenes such as amphotericin B disrupt fungal membrane integrity by binding to ergosterol. Echinocandins target the fungal cell wall by inhibiting the synthesis of beta-glucan, a key structural component. These diverse mechanisms highlight the versatility of antifungal drugs in combating fungal infections which shows the figure 1.



Figure 1: Categories of antifungal medications and their fundamental mechanisms of action

1.1 Antifungal Classes:

Antifungal classes constitute a diverse array of therapeutic agents essential for combating fungal infections. Each class exhibits distinctive mechanisms of action, targeting specific components vital for fungal viability. Polyenes, exemplified by amphotericin B, function by binding to ergosterol in fungal cell membranes, causing membrane disruption and subsequent cell death (Wiedman et al. 2017). Azoles, including fluconazole and itraconazole, inhibit ergosterol synthesis, disrupting membrane integrity. Echinocandins such as caspofungin target β-glucan synthesis in the fungal cell wall, impairing structural integrity. Allylamines, typified by terbinafine, inhibit ergosterol synthesis by targeting squalene epoxidase. Pyrimidine analogs interfere with nucleic acid synthesis, exemplified by flucytosine. The mechanisms and nuances of each antifungal class is pivotal for tailoring effective treatment strategies against a spectrum of fungal pathogens (Campoy and Adrio 2017).

Ergosterol:

Ergosterol is a crucial sterol found in the cell membranes of fungi, playing a fundamental role in maintaining membrane integrity and fluidity. Analogous to cholesterol in animal cells, ergosterol contributes to the structural stability of fungal cell membranes. Its presence is vital for various cellular functions, including maintaining osmotic balance and facilitating membrane-bound enzymatic activities. The unique composition of ergosterol in fungal membranes serves as a target for certain antifungal agents, such as polyenes and azoles, which disrupt fungal cell membranes by binding to or inhibiting the synthesis of ergosterol (Cruz and Wuest 2023; Du Bois et al. 2022). Consequently, interference with ergosterol function leads to increased membrane permeability, impairing the structural integrity of the fungal cell and ultimately resulting in cell death. Due to its essential role in fungal physiology and its absence in human cells, ergosterol remains a pivotal target for the development of antifungal drugs with selective toxicity against fungal pathogens (Ghannoum and Rice 1999; Kaplancıklı et al. 2017).

Cell wall of fungal:

In fungal cells, the cell wall is a critical and distinctive structure that plays a crucial role in maintaining cell shape, structural integrity, and protection against environmental stresses. Unlike animal cells, fungi possess a rigid cell wall surrounding their cell membrane. The primary components of the fungal cell wall are glucans, complex carbohydrates made up of glucose molecules, and chitin, a

nitrogen-containing polysaccharide (Edwards 2012). The fungal cell wall serves as a dynamic barrier that not only provides structural support but also facilitates essential cellular processes such as nutrient uptake and communication with the environment (Arana et al. 2009). Additionally, it acts as a defense mechanism against various external factors, including host immune responses and antifungal agents. Understanding the composition and organization of the fungal cell wall is integral to developing antifungal therapies. Some antifungal drugs, such as echinocandins, specifically target components of the fungal cell wall, disrupting its synthesis and leading to the weakening and eventual lysis of the fungal cell. The unique features of the fungal cell wall make it a key focus in research aimed at developing targeted and effective antifungal treatments while minimizing the impact on host cells (Cortés et al. 2019; Edwards 2012). Ergosterol plays multiple crucial roles in fungal infection cells. Firstly, it serves as a key component of the fungal cell membrane, providing structural integrity and stability. Secondly, ergosterol is essential for maintaining the fluidity and permeability of the membrane, facilitating vital processes such as nutrient uptake and waste elimination. Lastly, ergosterol acts as a target for many antifungal drugs, as its disruption can lead to cell membrane dysfunction and ultimately fungal cell death. Overall, the presence and functionality of ergosterol are indispensable for the survival and virulence of fungal pathogens which shows the figure 2.



Figure 2: Multiple role of Ergosterol in fungal infection cells.

1.2 Mechanisms of Action in Fungal Diseases:

This section delves into the intricate mechanisms employed by antifungal agents to combat fungal pathogens. From the disruption of fungal cell membranes and inhibition of ergosterol synthesis to interference with cell wall construction and nucleic acid synthesis, a comprehensive understanding of these mechanisms is essential for optimizing therapeutic outcomes. Fungal diseases, caused by various pathogenic fungi, involve complex interactions between the host and the invading microorganisms. The mechanisms of action by which fungi cause diseases can vary based on the specific species and the host's immune response (Asad 2022; Ashley et al. 2006; B. Liu et al. 2022). Some general mechanisms Fungi often enter the host through inhalation, ingestion, or direct contact. Adhesion to host cells and tissues is facilitated by fungal structures such as hyphae, spores, or specialized adhesion proteins (Smirnova and Kochetov 2016). Pathogenic fungi possess mechanisms to invade host tissues, utilizing enzymes like proteases and lipases to break down host barriers. The ability to form hyphae or pseudohyphae allows invasive growth into host tissues (Cotter and Kavanagh 2000; I. Sharma 2021). Fungi can modulate the host immune response to establish infection. This includes the evasion of phagocytosis, inhibition of immune cell activation, and the

ability to survive and replicate within host cells (Graf et al. 2023). Some fungi produce toxins that contribute to pathogenicity. For example, aflatoxins produced by Aspergillus species are known carcinogens, and mycotoxins can have harmful effects on host cells (Tsuge et al. 2013). Fungal pathogens can form biofilms on host surfaces, providing a protective environment that enhances resistance to host defenses and antifungal treatments. These mechanisms are crucial for developing targeted therapeutic approaches to combat fungal diseases (Vanzolini et al. 2022). Antifungal agents disrupt specific fungal processes, such as cell wall synthesis, ergosterol biosynthesis, or nucleic acid replication, to impede the growth and survival of pathogenic fungi. The constant interplay between the host and fungal pathogens underscores the importance of comprehensive research to unravel the intricacies of fungal pathogenesis and devise effective treatment strategies (C. W. Zhang et al. 2023).

1.2.1 Molecular mechanism of fungal disease:

Antifungal resistance represents a growing challenge in the effective management of fungal infections, posing significant threats to public health. Understanding the molecular mechanisms underlying antifungal resistance is crucial for developing strategies to combat this phenomenon. Several key mechanisms contribute to the development of resistance in fungal pathogens: Genetic alterations in crucial genes involved in the antifungal target pathways can confer resistance. For example, mutations in the genes encoding enzymes involved in ergosterol biosynthesis, the target of azoles, can lead to reduced drug efficacy (Ball et al. 2019). Fungi can develop resistance by upregulating efflux pumps, cellular transporters that actively remove antifungal drugs from the fungal cell. This reduces the intracellular concentration of the drug, diminishing its effectiveness. Overexpression of efflux pump genes is a common mechanism seen in azole-resistant strains. Fungal pathogens may develop resistance by modifying the drug target itself. This could involve changes in the structure or expression of the target proteins, making them less susceptible to inhibition by antifungal agents. Fungi often form biofilms on surfaces, and these biofilms exhibit increased resistance to antifungal agents (Z. Q. Zhang et al. 2021). The extracellular matrix of biofilms can physically protect fungal cells from the effects of antifungal drugs, contributing to persistent infections. Heteroresistance refers to the coexistence of both susceptible and resistant populations within a single fungal strain (Medeiros et al. 2022). This phenomenon complicates treatment outcomes, as the resistant subpopulation can survive and proliferate even in the presence of antifungal therapy. Fungi activate stress response pathways as a survival strategy against antifungal stress. Activation of stress response pathways can lead to changes in cellular processes that enhance the fungus's ability to withstand the effects of antifungal drugs. Acquisition of resistance genes through horizontal gene transfer can contribute to the spread of antifungal resistance among different fungal strains or species. This mechanism can accelerate the emergence of resistance in clinical settings (Cowen et al. 2015).

1.3 Clinical Applications:

The applications of antifungal agents in clinical settings, ranging from topical treatments for superficial infections to systemic therapies for severe fungal diseases. Emphasis is placed on the spectrum of activity, pharmacokinetics, and considerations for individual patient profiles in tailoring antifungal regimens. Clinical applications of antifungal agents are pivotal in the management of fungal diseases, ranging from superficial infections to life-threatening systemic conditions (Gholami et al. 2023). In dermatology, antifungal creams and ointments, often containing azoles like clotrimazole or terbinafine, are widely employed to treat common skin fungal infections such as ringworm and athlete's foot. For mucocutaneous candidiasis, oral azoles like fluconazole are frequently prescribed (Mantilla-Florez et al. 2021). In systemic fungal infections, echinocandins, such as caspofungin, are utilized in hospitalized patients. Azoles like voriconazole find application in treating invasive aspergillosis, while amphotericin B, a polyene, remains a potent choice for severe systemic mycoses (Cafarchia et al. 2013). Antifungal prophylaxis is often employed in immunocompromised patients to prevent opportunistic fungal infections. The clinical applications of

antifungal agents are diverse, reflecting the broad spectrum of fungal diseases they address, and their judicious use is crucial in ensuring optimal patient outcomes (Strati et al. 2016).

1.4 Challenges and Emerging Issues:

Despite advancements, challenges persist in antifungal therapy, including resistance patterns and limitations in available treatments. This section addresses these challenges, providing insights into emerging issues and potential avenues for overcoming therapeutic hurdles. Fungal diseases present a complex and evolving set of challenges in the field of healthcare and medical research. Some of the prominent challenges and emerging issues associated with fungal diseases include. There has been a notable rise in the incidence and diversity of fungal infections, affecting a broad spectrum of individuals from immunocompromised patients to healthy individuals. The emergence of drug-resistant strains further complicates treatment strategies (Ali Malayeri et al. 2018; Janbon et al. 2019). The repertoire of antifungal drugs is limited compared to antibacterial agents, and the options for treating certain fungal infections are often constrained. This scarcity underscores the urgency for the development of new and effective antifungal agents. Similar to bacterial resistance, antifungal resistance is on the rise. Fungi can develop resistance through various mechanisms, including genetic mutations and the overexpression of efflux pumps. This poses a significant challenge to the successful management of fungal infections. Diagnosing fungal infections can be challenging, often leading to delays in appropriate treatment (Lofgren and Stajich 2021; Veríssimo et al. 2022). The lack of rapid and accurate diagnostic tools contributes to the difficulty in distinguishing fungal from bacterial or viral infections, hampering timely intervention. Individuals with compromised immune systems, such as those undergoing chemotherapy or organ transplantation, are particularly vulnerable to fungal infections. The increasing population of immunocompromised patients amplifies the severity and frequency of fungal diseases. Changes in environmental conditions, including climate change and alterations in ecosystems, can influence the prevalence and distribution of fungal pathogens. This dynamic interaction between the environment and fungal diseases adds complexity to understanding and controlling their spread. Increased global travel and interconnectedness facilitate the spread of fungal pathogens across borders. This poses challenges for public health systems in terms of monitoring, prevention, and control of fungal diseases on a global scale. Many pathogenic fungi can form biofilms on various surfaces, including medical devices and tissues. Biofilm formation enhances resistance to antifungal agents and immune responses, leading to persistent and recurrent infections (Chakrabarti and Singh 2019). Compared to bacterial or viral infections, public awareness regarding fungal diseases is often limited. This lack of awareness can result in delayed diagnosis and treatment, contributing to the overall burden of these infections. Despite the increasing significance of fungal diseases, there are still gaps in our understanding of the biology, epidemiology, and pathogenesis of many fungal pathogens (Rottstock et al. 2014; Schikora-Tamarit and Gabaldón 2022). The challenges and emerging issues of antifungal drugs would typically depict several key elements. Firstly, it would outline the increasing incidence of drug-resistant fungal infections, posing a significant challenge to current treatment strategies. Secondly, it might highlight the limited availability of novel antifungal agents, hindering efforts to combat evolving fungal pathogens effectively. Lastly, the diagram could indicate the importance of addressing systemic factors such as immunocompromised patient populations and environmental factors contributing to the spread of fungal infections, underscoring the complexity of managing antifungal resistance in the broader context of healthcare which shows the figure 3.



Figure 3: Flow diagram of challenges and emerging issues of antifungal

1.5 Combination Therapies:

In response to the growing threat of antifungal resistance, this section examines the concept of combination therapies. The paper discusses recent studies exploring synergistic effects and improved outcomes when combining different antifungal classes, offering a glimpse into potential future treatment strategies. Combination therapies represent a promising approach in the battle against fungal diseases, offering a synergistic and multifaceted strategy to overcome challenges such as drug resistance and treatment complexities (Belanger et al. 2015; Su et al. 2022). In the realm of fungal infections, the efficacy of single antifungal agents can be compromised by the emergence of resistant strains. The integration of multiple antifungal classes, such as combining azoles with echinocandins or polyenes, has demonstrated enhanced therapeutic outcomes by targeting different aspects of fungal cell biology simultaneously. This synergistic approach not only improves the overall efficacy but also helps to mitigate the development of resistance. Additionally, combination therapies broaden the spectrum of coverage, providing a more comprehensive solution for complex fungal infections or cases with uncertain etiology. However, challenges persist, including potential drug interactions, toxicity concerns, and the need for tailored regimens based on the specific fungal pathogen and host factors. As research in this field advances, the exploration of optimal combinations and the development of novel therapeutic strategies continue to hold promise for more effective management of fungal diseases (Johnson et al. 2004; Marr et al. 2015). Antifungal combinations may be used in certain cases to enhance effectiveness or to target different types of fungi. Common antifungal classes include azoles, echinocandins, and polyenes (Chen et al. 2014). Here are a few examples of antifungal used drugs classification shows figure 4.



Figure 4: Flow diagram for the classification of antifungal drugs based on their mode of action, along with the names of drugs used in the management of fungal infections

Combining antifungal medications may be considered when a patient is not responding to a single drug, when dealing with a severe infection, or when there is a need to cover a broader spectrum of fungi. However, the use of combination therapy is determined on a case-by-case basis, and healthcare professionals will carefully weigh the potential benefits and risks (Belanger et al. 2015; Campitelli et al. 2017).

In addressing challenges associated with antifungal treatment, one viable option is the utilization of drug combinations. The concurrent use of multiple antifungal medications offers the potential for increased efficacy, primarily by targeting multiple points of action. This approach not only enhances the overall antifungal activity but also contributes to a reduction in toxicity, as the individual drugs can be administered at lower doses (M. Sharma et al. 2010). The synergistic effects achieved through combination therapy can lead to improved outcomes, while concurrently mitigating the risk of antagonist interactions. To assess the impact of drug combinations, particularly *in vitro*, the checkerboard method serves as a valuable tool. This method allows researchers to systematically evaluate the interactions between different drugs, providing insights into their combined effectiveness against fungal pathogens (Pagano et al. 2013).

Studies investigating the *in vitro* and *in vivo* combination of azoles with Amphotericin B (AmB) often report a lack of synergistic activity, primarily attributed to the shared target of both drug classes – ergosterol. Azoles, by inhibiting ergosterol biosynthesis, reduce the availability of this crucial fungal cell membrane component, potentially limiting the binding sites for polyenes like AmB (Fioriti et al. 2022; Liang et al. 2023). Consequently, this common target may undermine the anticipated synergistic effects between azoles and AmB. Despite this general trend, there have been instances of successful treatment for invasive mucormycosis through the combination of AmB and posaconazole. This particular combination, despite the apparent target overlap with azoles, has demonstrated efficacy in certain cases. The success of AmB and posaconazole in treating invasive mucormycosis suggests that factors beyond the shared ergosterol target may influence the therapeutic outcome (Rodrigues et al. 2018). The intricate interplay between drug mechanisms, the specific characteristics of the fungal infection, and the pharmacokinetics of the drugs involved could contribute to the observed efficacy in this particular antifungal combination. Further research is warranted to unravel the nuances of these interactions and to optimize antifungal strategies for combating diverse fungal infections (Raad et al. 2015).

Interactions between antifungal agents and non-antifungal compounds have been explored for their potential to enhance antifungal activity. Triclosan, known for its antimicrobial properties and

commonly found in personal care products like soap and toothpaste, has demonstrated *in vitro* synergistic effects with fluconazole (FLZ) against *Candida albicans*. Additionally, triclosan exhibits activity against Cryptococcus neoformans, activating the apoptosis pathway, and shows synergistic effects when combined with amphotericin B (AmB) and FLZ. Considering the crucial role of ion homeostasis in fungal disease development, ion chelators have been investigated for treating fungal infections (Nikoomanesh et al. 2023). However, despite their effectiveness in maintaining ion balance, these chelators did not exhibit favorable responses when combined with antifungal drugs in in vitro studies. Interestingly, calcium channel blockers, primarily used for cardiovascular disorders, have shown antifungal activity. Recent research highlights that calcium channel blockers such as amlodipine, nifedipine, benidipine, and flunarizine present synergistic activity with FLZ against *C. albicans* isolates resistant to FLZ. This synergistic effect occurs through a mechanism unrelated to efflux pump inactivation. These findings suggest that exploring the interactions between antifungal agents and non-antifungal compounds may provide valuable insights into novel therapeutic approaches for fungal infections, potentially enhancing the efficacy of existing antifungal medications (Verweij et al. 2015). Further research is needed to better understand the underlying mechanisms and evaluate the clinical applicability of these synergistic combinations (S. Liu et al. 2016).

Natural compounds with antifungal properties are often reported to exhibit *in vitro* synergistic effects when used in combination with conventional antifungal drugs, resulting in a reduction in the required concentrations of both substances (DIN et al. 2023; Sienkiewicz and Członka 2022). An example of this synergy involves the natural substance beauvericin, which, when used in conjunction with traditional antifungals, demonstrated the ability to inhibit efflux pumps and morphogenesis in fluconazole-resistant *Candida albicans*. This collaboration enhanced the effectiveness of the azole, showcasing the potential of combining natural antifungal compounds with existing medications to combat drug resistance and improve treatment outcomes (Shekhar-Guturja et al. 2016).

1.6 Immunomodulation in Antifungal Therapy:

Traditional antifungal approaches, the review explores the interface between antifungal agents and the host's immune response. This includes discussions on immunomodulatory strategies to enhance the innate immune system's ability to combat fungal infections. The interplay between immunomodulation and antifungal therapy represents a promising avenue for addressing fungal diseases. Fungi can cause a spectrum of infections, from superficial conditions to invasive and life-threatening diseases, particularly in immunocompromised individuals (Bugeda et al. 2020). Immunomodulatory approaches seek to enhance the host's immune response against fungal pathogens, recognizing the importance of a balanced and robust immune system in preventing and combating infections. In the context of fungal diseases, the immune system, comprising innate and adaptive components, plays a pivotal role in recognizing and eliminating fungal invaders. Immunomodulation strategies aim to bolster these natural defense mechanisms. This may involve the use of immunostimulatory agents, vaccines, or therapies that enhance the activity of immune cells involved in fungal clearance (Parolin et al. 2021). The intricacies of the host-fungal interaction is essential for developing effective immunomodulatory interventions. In certain fungal infections, compromised immunity is a significant factor, making immunomodulation a crucial adjunct to antifungal therapy. By harnessing the immune system's power, researchers and clinicians aim to not only treat existing fungal infections but also prevent their recurrence in vulnerable populations. In this context, ongoing research explores the integration of immunomodulatory approaches with traditional antifungal agents (Gao et al. 2016). This synergistic strategy aims to not only eliminate the fungal pathogen directly but also empower the host's immune system for a more comprehensive and sustained defense against fungal diseases. As our understanding of immunology and fungal pathogenesis advances, the prospect of tailored and effective immunomodulatory antifungal therapies holds great promise for improving outcomes in the management of fungal diseases (Ademe 2020; Ben-Ami et al. 2008).

1.7 Nanoformulation for topical antifungal:

Nanoformulations for topical antifungal applications involve the use of nanotechnology to enhance the delivery, stability, and efficacy of antifungal agents on the skin. Nanoparticles, nanoemulsions, nanogels, and other nanostructured systems are commonly employed for this purpose. The key advantages of nanoformulations in topical antifungal treatments include improved drug penetration, sustained release, and enhanced therapeutic outcomes. Topical antifungal agents and their nanoformulations represent a critical area in the field of dermatology, providing enhanced formulations for the treatment of fungal skin infections. These formulations are designed to improve drug delivery, skin penetration, and overall therapeutic efficacy. Here, we explore common topical antifungal agents and their corresponding nanoformulation. Different types of nanoformulation shows table no. 1

Table 1: Different types of topical nanoformulation for antifungals agents

S. No.	Nanoformulation Type	Description	References
1.	Lipid Nanoparticles (LNPs)	Nanoparticles composed of lipids for improved drug stability, solubility, and controlled release.	(Füredi et al. 2017; Jung et al. 2009)
2.	Nanoemulsions	Nanoscale emulsions with improved drug penetration and release properties, enhancing topical antifungal drug efficacy.	(Gong et al. 2021)
3.	Nanogels	Three-dimensional (3D) networks of nanosized hydrogel particles, offering sustained release and prolonged skin contact.	(Deseta et al. 2023)
4.	Solid Lipid Nanoparticles (SLNs)	Lipid-based nanoparticles that enhance drug loading, stability, and skin penetration, providing sustained release on the skin.	(Rarokar et al. 2022)
5.	Nanostructured Lipid Carriers (NLCs)	Modified lipid carriers with improved drug encapsulation and release properties compared to traditional lipid nanoparticles.	(Katopodi and Detsi 2021)
6.	Dendrimers	Highly branched macromolecules with nanoscale dimensions that can encapsulate antifungal drugs, offering controlled release and inherent antifungal properties.	(Winnicka et al. 2011)
7.	Polymeric Nanoparticles	Nanoparticles made from biodegradable polymers for sustained drug release and enhanced skin penetration.	(Ho et al. 2020)
8.	Nanocapsules	Capsule-like structures encapsulating antifungal drugs, providing controlled release and improving drug stability.	(Hussein et al. 2020)
9.	Nanosuspensions	Stable colloidal dispersions of drug nanoparticles in a liquid medium, offering improved drug solubility and skin permeation.	(Al-Obaidi et al. 2022)
10.	Silver Nanoparticles	Nanoparticles of silver with inherent antifungal properties, used for both antimicrobial and antifungal applications.	(Mussin and Giusiano 2022)
11.	Chitosan Nanoparticles	Nanoparticles made from chitosan, a biocompatible polymer, for enhanced drug delivery and bioavailability on the skin.	(Poznanski et al. 2023)
12.	Carbon Nanotubes	Tubular structures with high surface area, offering potential for improved drug delivery and skin penetration.	(Anzar et al. 2020)
13.	Peptide Nanoparticles	Nanoparticles made from peptides, allowing for targeted drug delivery and enhanced therapeutic effects.	(Maximiano et al. 2022)
14.	Quantum Dots	Semiconductor nanocrystals with unique optical properties, offering potential applications in imaging and drug delivery for antifungal agents.	(Chand et al. 2021)
15.	Cyclodextrin-based Nanoparticles	Nanoparticles formed using cyclodextrins for improved drug solubility, stability, and release on the skin.	(Man et al. 2022)

1.8 Future Directions and Research Gaps:

In summary, this scientific review synthesizes current knowledge of antifungal agents, providing a comprehensive understanding of their mechanisms and applications. By addressing challenges and exploring emerging strategies, it aims to contribute to the advancement of antifungal therapy and ultimately improve patient care. The future directions in addressing fungal diseases hold significant promise and challenges (Chanyachailert et al. 2023). One key avenue lies in the development of more targeted and selective antifungal therapies. Precision medicine approaches, including the identification of specific genetic markers in fungal pathogens, could pave the way for personalized treatments tailored to the individual characteristics of the infection (Lírio et al. 2019). Additionally, the exploration of novel antifungal agents, such as those derived from natural sources or through innovative drug discovery methods, holds considerable potential. Advancements in immunomodulatory strategies, including the development of vaccines and therapies that enhance the host immune response against fungal infections, represent another frontier. Improved diagnostic techniques, such as rapid and accurate point-of-care tests, will be crucial for early detection and intervention (Chanyachailert et al. 2023; W. Liu et al. 2020). Furthermore, addressing the growing concern of antifungal resistance requires ongoing research into alternative treatment modalities and a deeper understanding of the complex interactions between fungi and the human host. As we navigate the future of combating fungal diseases, collaboration between researchers, clinicians, and pharmaceutical industries will be essential to bring about innovative solutions and enhance our arsenal against these resilient pathogens (Plaszkó et al. 2021).

1.9 Conclusion:

In conclusion offers a panoramic view of the intricate landscape of antifungal therapy. The comprehensive exploration of various antifungal classes, their mechanisms of action, and clinical applications underscores the dynamic nature of this field. As our understanding of fungal infections evolves, so must our approach to antifungal treatment. The review has highlighted the significance of knowing the mechanisms by which antifungal agents combat infections, enabling healthcare professionals to make informed decisions in tailoring therapies to individual patients. Challenges in antifungal therapy, such as the rise of drug-resistant strains and the limited arsenal of treatment options, have been discussed. The acknowledgment of these challenges serves as a call to action, urging researchers and clinicians to collaborate in finding innovative solutions and novel therapeutic avenues. The exploration of combination therapies and the role of immunomodulation adds layers to the ongoing narrative of antifungal research. The review emphasizes the need for a holistic approach, combining traditional antifungal agents with emerging strategies to enhance efficacy and address the complexities of managing fungal infections. Looking ahead, the future of antifungal therapy lies in the development of novel agents, precision medicine tailored to individual patient profiles, and advancements in diagnostics for early and accurate identification. This comprehensive review serves not only as a resource for current practices but also as a catalyst for future investigations and advancements in the ongoing battle against fungal infections. In the pursuit of more effective, targeted, and personalized antifungal therapies, collaboration across disciplines and a commitment to ongoing research will be essential. As we navigate the ever-evolving field of antifungal agents, this review stands as a testament to the progress made and the exciting possibilities that lie ahead in the realm of fungal infection management.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References:

1. Ademe, M. (2020). Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges. Frontiers in Cellular and Infection Microbiology.
2. Al-Obaidi, H., Petraityte, I., Hibbard, T., Majumder, M., Kalgudi, R., & Zariwala, M. G. (2022).

Antifungal nanosuspensions with surfactants and silver for the treatment of onychomycosis. European Journal of Pharmaceutics and Biopharmaceutics, 179, 194–205.
3. Ali Malayeri, F., Rezaei, A., & Raiesi, O. (2018). Antifungal agents: Polyene, azole, antimetabolite, other and future agents. Journal of Basic Research in Medical Sciences, 5(2), 48–55.
4. Anzar, N., Hasan, R., Tyagi, M., Yadav, N., & Narang, J. (2020). Carbon nanotube - A review on Synthesis, Properties and plethora of applications in the field of biomedical science. Sensors International, 1, 100003.
5. Arana, D. M., Prieto, D., Román, E., Nombela, C., Alonso-Monge, R., & Pla, J. (2009). The role of the cell wall in fungal pathogenesis. Microbial Biotechnology, 2(3), 308–320.
6. Asad, S. A. (2022). Mechanisms of action and biocontrol potential of Trichoderma against fungal plant diseases - A review. Ecological Complexity, 49, 100978.
7. Ashley, E. S. D., Lewis, R., Lewis, J. S., Martin, C., & Andes, D. (2006). Pharmacology of Systemic Antifungal Agents. Clinical Infectious Diseases, 43(Supplement_1), S28–S39.
8. Ball, B., Bermas, A., Carruthers-Lay, D., & Geddes-McAlister, J. (2019). Mass spectrometry-based proteomics of fungal pathogenesis, host-fungal interactions, and antifungal development. Journal of Fungi, 5(2), p.52.
9. Belanger, E. S., Yang, E., & Forrest, G. N. (2015). Combination Antifungal Therapy: When, Where, and Why. Current Clinical Microbiology Reports, 2(2), 67–75.
10. Ben-Ami, R., Lewis, R. E., & Kontoyiannis, D. P. (2008). Immunocompromised Hosts: Immunopharmacology of Modern Antifungals. Clinical Infectious Diseases, 47(2), 226–235.
11. Brauer, V. S., Rezende, C. P., Pessoni, A. M., De Paula, R. G., Rangappa, K. S., Nayaka, S. C., et al. (2019). Antifungal agents in agriculture: Friends and foes of public health. Biomolecules, 9(10), p.521.
12. Bugeda, A., Garrigues, S., Gandía, M., Manzanares, P., Marcos, J. F., & Coca, M. (2020). The Antifungal Protein AfpB Induces Regulated Cell Death in Its Parental Fungus Penicillium digitatum. mSphere, 5(4).
13. Cafarchia, C., Figueredo, L. A., & Otranto, D. (2013). Fungal diseases of horses. Veterinary Microbiology, 167(1–2), 215–234.
14. Campitelli, M., Zeineddine, N., Samaha, G., & Maslak, S. (2017). Combination Antifungal Therapy: A Review of Current Data. Journal of Clinical Medicine Research, 9(6), 451–456.
15. Campoy, S., & Adrio, J. L. (2017). Antifungals. Biochemical Pharmacology, 133, 86–96.
16. Chakrabarti, A., & Singh, S. (2019). Challenges in invasive fungal disease. In Advancing Frontiers in Mycology and Mycotechnology: Basic and Applied Aspects of Fungi, pp.457-478.
17. Chand, P., Kumari, S., Mondal, N., Singh, S. P., & Prasad, T. (2021). Synergism of Zinc Oxide Quantum Dots with Antifungal Drugs : Potential Approach for Combination Therapy against Drug Resistant Candida albicans, 3(May), 1–13.
18. Chanyachailert, P., Leeyaphan, C., & Bunyaratavej, S. (2023). Cutaneous Fungal Infections Caused by Dermatophytes and Non-Dermatophytes: An Updated Comprehensive Review of Epidemiology, Clinical Presentations, and Diagnostic Testing. Journal of Fungi, 9(6), p.669.
19. Chen, X., Ren, B., Chen, M., Liu, M.-X., Ren, W., Wang, Q.-X., et al. (2014). ASDCD: Antifungal Synergistic Drug Combination Database. PLoS ONE, 9(1), e86499.
20. Cortés, J. C. G., Curto, M.-Á., Carvalho, V. S. D., Pérez, P., & Ribas, J. C. (2019). The fungal cell wall as a target for the development of new antifungal therapies. Biotechnology Advances, 37(6), 107352.
21. Cotter, G., & Kavanagh, K. (2000). Adherence mechanisms of Candida albicans. British journal of biomedical science, 57(3), 241–9.
22. Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015). Mechanisms of Antifungal Drug Resistance. Cold Spring Harbor Perspectives in Medicine, 5(7), a019752.
23. Cruz, R., & Wuest, W. M. (2023). Beyond ergosterol: Strategies for combatting antifungal resistance in Aspergillus fumigatus and Candida auris. Tetrahedron, 133, 133268.
24. Deseta, M. L., Sponton, O. E., Finos, M. B., Cuffia, F., Torres-Nicolini, A., Álvarez, V. A., et al.

(2023). Development of Antifungal Films from Nanocomplexes Based on Egg White Protein Nanogels and Phenolic Compounds. Food Biophysics, 18(2), pp.273-288.
25. DIN, A., MITREA, I., & MITREA, R. (2023). Natural compounds: an effective and eco-friendly strategies for controlling and combating plant pathogens. Notulae Botanicae Horti Agrobotanici Cluj-Napoca, 51(1), 12991.
26. Du Bois, A. C., Xue, A., Pham, C., Revie, N. M., Meyer, K. J., Yashiroda, Y., et al. (2022). High-Throughput Chemical Screen Identifies a 2,5-Disubstituted Pyridine as an Inhibitor of Candida albicans Erg11. mSphere, 7(3), pp.e00075-22.
27. Edwards, J. E. (2012). Fungal cell wall vaccines: an update. Journal of Medical Microbiology, 61(7), 895–903.
28. Fioriti, S., Brescini, L., Pallotta, F., Canovari, B., Morroni, G., & Barchiesi, F. (2022). Antifungal Combinations against Candida Species: From Bench to Bedside. Journal of Fungi, 8(10), 1077.
29. Füredi, P., Pápay, Z. E., Kovács, K., Kiss, B. D., Ludányi, K., Antal, I., & Klebovich, I. (2017). Development and characterization of the voriconazole loaded lipid-based nanoparticles. Journal of Pharmaceutical and Biomedical Analysis, 132, 184–189.
30. Gao, L., Jiang, S., Sun, Y., Deng, M., Wu, Q., Li, M., & Zeng, T. (2016). Evaluation of the effects of photodynamic therapy alone and combined with standard antifungal therapy on planktonic cells and biofilms of Fusarium spp. and Exophiala spp. Frontiers in Microbiology, 7, p.617.
31. Ghannoum, M. A., & Rice, L. B. (1999). Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance. Clinical Microbiology Reviews, 12(4), 501–517.
32. Gholami, L., Shahabi, S., Jazaeri, M., Hadilou, M., & Fekrazad, R. (2023). Clinical applications of antimicrobial photodynamic therapy in dentistry. Frontiers in Microbiology, 13, p.1020995.
33. Gong, X., Su, X., & Liu, H. (2021). Diallyl Trisulfide, the Antifungal Component of Garlic Essential Oil and the Bioactivity of Its Nanoemulsions Formed by Spontaneous Emulsification. Molecules, 26(23), 7186.
34. Graf, K. T., Liu, H., Filler, S. G., & Bruno, V. M. (2023). Depletion of Extracellular Chemokines by Aspergillus Melanin. mBio, 14(3).
35. Ho, H. N., Le, T. G., Dao, T. T. T., Le, T. H., Dinh, T. T. H., Nguyen, D. H., et al. (2020). Development of Itraconazole-Loaded Polymeric Nanoparticle Dermal Gel for Enhanced Antifungal Efficacy. Journal of Nanomaterials, 2020, 1–11.
36. Hussein, A., Abdel-Mottaleb, M. M. A., El-assal, M., & Sammour, O. (2020). Novel biocompatible essential oil-based lipid nanocapsules with antifungal properties. Journal of Drug Delivery Science and Technology, 56, p.101605.
37. Janbon, G., Quintin, J., Lanternier, F., & D'Enfert, C. (2019). Studying fungal pathogens of humans and fungal infections: fungal diversity and diversity of approaches. Genes & Immunity, 20(5), 403–414.
38. Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004). Combination Antifungal Therapy. Antimicrobial Agents and Chemotherapy, 48(3), pp.693-715.
39. Jung, S. H., Lim, D. H., Jung, S. H., Lee, J. E., Jeong, K.-S., Seong, H., & Shin, B. C. (2009). Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. European Journal of Pharmaceutical Sciences, 37(3–4), 313–320.
40. Kaplancıklı, Z. A., Levent, S., Osmaniye, D., Sağlık, B. N., Çevik, U. A., Çavuşoğlu, B. K., et al. (2017). Synthesis and Anticandidal Activity Evaluation of New Benzimidazole-Thiazole Derivatives. Molecules, 22(12), 2051.
41. Katopodi, A., & Detsi, A. (2021). Solid Lipid Nanoparticles and Nanostructured Lipid Carriers of natural products as promising systems for their bioactivity enhancement: The case of essential oils and flavonoids. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 630, p.127529.
42. Kumar, V., Ain, S., Kumar, B., Ain, Q., & Gaurav. (2020). Optimization and evaluation of topical gel containing solid lipid nanoparticles loaded with luliconazole and its anti-fungal activity. In International Journal of Pharmaceutical Research (Vol. 12, pp. 2901–2912).

43. Liang, P., Song, J., & Liu, Q. (2023). Interactions between antifungals and everolimus against Cryptococcus neoformans. Frontiers in Cellular and Infection Microbiology, 13, p.1131641.
44. Lírio, J., Giraldo, P. C., Amaral, R. L., Sarmento, A. C. A., Costa, A. P. F., & Goncalves, A. K. (2019). Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: A systematic review protocol. BMJ Open, 9(5).
45. Liu, B., Stevens-Green, R., Johal, D., Buchanan, R., & Geddes-McAlister, J. (2022). Fungal pathogens of cereal crops: Proteomic insights into fungal pathogenesis, host defense, and resistance. Journal of Plant Physiology, 269, 153593.
46. Liu, S., Yue, L., Gu, W., Li, X., Zhang, L., & Sun, S. (2016). Synergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicans. PLoS ONE, 11(3), p.e0150859.
47. Liu, W., Yuan, L., & Wang, S. (2020). Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall. Journal of Medicinal Chemistry, 63(21), pp.12429-12459.
48. Lofgren, L. A., & Stajich, J. E. (2021). Fungal biodiversity and conservation mycology in light of new technology, big data, and changing attitudes. Current Biology, 31(19), pp.R1312-R1325.
49. Man, H., Hnin, S., Maw, P. D., & Loftsson, T. (2022). A Current Overview of Cyclodextrin-Based Nanocarriers for Enhanced Antifungal Delivery, 1–21.
50. Mani Chandrika, K. V. S., & Sharma, S. (2020). Promising antifungal agents: A minireview. Bioorganic & Medicinal Chemistry, 28(7), 115398.
51. Mantilla-Florez, Y. F., Tuta-Quintero, E., Brito-Rodriguez, A. J., & Clavijo-Moreno, L. C. (2021). Candidiasis y Candida Albicans. Boletín de Malariología y Salud Ambiental, 61(3), 391–400.
52. Marr, K. A., Schlamm, H. T., Herbrecht, R., Rottinghaus, S. T., Bow, E. J., Cornely, O. A., et al. (2015). Combination antifungal therapy for invasive aspergillosis a randomized trial. Annals of Internal Medicine, 162(2), pp.81-89.
53. Maximiano, M. R., Rios, T. B., Campos, M. L., Prado, G. S., Dias, S. C., & Franco, O. L. (2022). Nanoparticles in association with antimicrobial peptides (NanoAMPs) as a promising combination for agriculture development. Frontiers in Molecular Biosciences, 9, p.890654.
54. Medeiros, C. I. S., de Sousa, M. N. A., Filho, G. G. A., Freitas, F. O. R., Uchoa, D. P. L., Nobre, M. S. C., et al. (2022). Antifungal activity of linalool against fluconazoleresistant clinical strains of vulvovaginal Candida albicans and its predictive mechanism of action. Brazilian Journal of Medical and Biological Research, 55.
55. Mussin, J., & Giusiano, G. (2022). Biogenic silver nanoparticles as antifungal agents. Frontiers in Chemistry, 10, p.1023542.
56. Nikoomanesh, F., Falahatinejad, M., Černáková, L., dos Santos, A. L. S., Mohammadi, S. R., Rafiee, M., et al. (2023). Combination of Farnesol with Common Antifungal Drugs: Inhibitory Effect against Candida Species Isolated from Women with RVVC. Medicina (Lithuania), 59(4), p.743.
57. Odds, F. C., Brown, A. J. P., & Gow, N. A. R. (2003). Antifungal agents: mechanisms of action. Trends in Microbiology, 11(6), 272–279.
58. Pagano, L., Cornely, O. A., Busca, A., Caira, M., Cesaro, S., Gasbarrino, C., et al. (2013). Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: A report from the SEIFEM and FUNGISCOPE registries. Haematologica, 98(10), p.e127.
59. Parolin, C., Abruzzo, A., Giordani, B., Oliver, J. C., Marangoni, A., Luppi, B., & Vitali, B. (2021). Anti-candida activity of hyaluronic acid combined with lactobacillus crispatus lyophilised supernatant: A new antifungal strategy. Antibiotics, 10(6), p.628.
60. Plaszkó, T., Szűcs, Z., Vasas, G., & Gonda, S. (2021). Effects of Glucosinolate-Derived Isothiocyanates on Fungi: A Comprehensive Review on Direct Effects, Mechanisms, Structure-Activity Relationship Data and Possible Agricultural Applications. Journal of Fungi, 7(7), 539.
61. Poznanski, P., Hameed, A., & Orczyk, W. (2023). Chitosan and Chitosan Nanoparticles: Parameters Enhancing Antifungal Activity. Molecules, 28(7), 2996.

62. Raad, I. I., Zakhem, A. El, Helou, G. El, Jiang, Y., Kontoyiannis, D. P., & Hachem, R. (2015). Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. International Journal of Antimicrobial Agents, 45(3), pp.283-288.
63. Rarokar, N. R., Menghani, S. S., Kerzare, D. R., Khedekar, P. B., Bharne, A. P., Alamri, A. S., et al. (2022). Preparation of Terbinafin-Encapsulated Solid Lipid Nanoparticles Containing Antifungal Carbopol® Hydrogel with Improved Efficacy: In Vitro, Ex Vivo and In Vivo Study. Pharmaceutics, 14(7), p.1393.
64. Rodrigues, C. F., Alves, D. F., & Henriques, M. (2018). Combination of posaconazole and amphotericin b in the treatment of candida glabrata biofilms. Microorganisms.
65. Rottstock, T., Joshi, J., Kummer, V., & Fischer, M. (2014). Higher plant diversity promotes higher diversity of fungal pathogens, while it decreases pathogen infection per plant. Ecology, 95(7), 1907–1917.
66. Ryder, N. S. (1999). Antifungal agents. IDrugs : the investigational drugs journal, 2(12), 1253–5.
67. Schikora-Tamarit, M. À., & Gabaldón, T. (2022). Using genomics to understand the mechanisms of virulence and drug resistance in fungal pathogens. Biochemical Society Transactions, 50(3), 1259–1268.
68. Sharma, I. (2021). Phytopathogenic fungi and their biocontrol applications. In Fungi Bio-Prospects in Sustainable Agriculture, Environment and Nano-Technology, Elsevier, pp. 155–188.
69. Sharma, M., Manoharlal, R., Negi, A. S., & Prasad, R. (2010). Synergistic anticandidal activity of pure polyphenol curcumin i in combination with azoles and polyenes generates reactive oxygen species leading to apoptosis. FEMS Yeast Research, 10(5), pp.570-578.
70. Shekhar-Guturja, T., Tebung, W. A., Mount, H., Liu, N., Köhler, J. R., Whiteway, M., & Cowen, L. E. (2016). Beauvericin potentiates azole activity via inhibition of multidrug efflux, blocks Candida albicans morphogenesis, and is effluxed via Yor1 and circuitry controlled by Zcf29. Antimicrobial Agents and Chemotherapy, 60(12), pp.7468-7480.
71. Sienkiewicz, N., & Członka, S. (2022). Natural Additives Improving Polyurethane Antimicrobial Activity. Polymers, 14(13), 2533.
72. Smirnova, O. G., & Kochetov, A. V. (2016). Plant cell wall and mechanisms of resistance to pathogens. Russian Journal of Genetics: Applied Research, 6(5), 622–631.
73. Strati, F., Di Paola, M., Stefanini, I., Albanese, D., Rizzetto, L., Lionetti, P., et al. (2016). Age and gender affect the composition of fungal population of the human gastrointestinal tract. Frontiers in Microbiology, 7, p.1227.
74. Su, S., Yan, H., Min, L., Wang, H., Chen, X., Shi, J., & Sun, S. (2022). The antifungal activity of caspofungin in combination with antifungals or non-antifungals against Candida species in vitro and in clinical therapy. Expert Review of Anti-infective Therapy, 20(2), 161–178.
75. Tsuge, T., Harimoto, Y., Akimitsu, K., Ohtani, K., Kodama, M., Akagi, Y., et al. (2013). Host-selective toxins produced by the plant pathogenic fungus Alternaria alternata. FEMS Microbiology Reviews, 37(1), pp.44-66.
76. Vanzolini, T., Bruschi, M., Rinaldi, A. C., Magnani, M., & Fraternale, A. (2022). Multitalented Synthetic Antimicrobial Peptides and Their Antibacterial, Antifungal and Antiviral Mechanisms. International Journal of Molecular Sciences, 23(1), 545.
77. Veríssimo, C., Toscano, C., Ferreira, T., Abreu, G., Simões, H., Diogo, J., et al. (2022). Invasive and Subcutaneous Infections Caused by Filamentous Fungi: Report from a Portuguese Multicentric Surveillance Program. Microorganisms, 10(5), 1010.
78. Verweij, P. E., Ananda-Rajah, M., Andes, D., Arendrup, M. C., Brüggemann, R. J., Chowdhary, A., et al. (2015). International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 21, pp.30-40.
79. Wiedman, G. R., Zhao, Y., Mustaev, A., Ping, J., Vishnubhotla, R., Johnson, A. T. C., & Perlin, D. S. (2017). An Aptamer-Based Biosensor for the Azole Class of Antifungal Drugs. mSphere,

2(4).
80. Winnicka, K., Sosnowska, K., Wieczorek, P., Sacha, P. T., & Tryniszewska, E. (2011). Poly(amidoamine) dendrimers increase antifungal activity of clotrimazole. Biological and Pharmaceutical Bulletin, 34(7), pp.1129-1133.
81. Zhang, C. W., Zhong, X. J., Zhao, Y. S., Rajoka, M. S. R., Hashmi, M. H., Zhai, P., & Song, X. (2023). Antifungal natural products and their derivatives: A review of their activity and mechanism of actions. Pharmacological Research - Modern Chinese Medicine, p.100262.
82. Zhang, Z. Q., Chen, T., Li, B. Q., Qin, G. Z., & Tian, S. P. (2021). Molecular basis of pathogenesis of postharvest pathogenic Fungi and control strategy in fruits: progress and prospect. Molecular Horticulture, 1(1), pp.1-10.